Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Watch CNBC’s full interview with Piper Sandler’s Michael Kantrowitz
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Power Lunch Michael Kantrowitz, chief investment strategist at Piper Sandler, joins ‘Power Lunch’ to discuss why he’s still bearish on the market and more. 06:36 12 minutes ago
Jim Cramer’s guide to investing: What do you do with a hot stock?
Sooner or later, virtually all hot stocks implode, said CNBC’s Jim Cramer. And according to him, it’s important for investors to know when to cash in before that happens. By hot stocks, Cramer means speculative companies with relatively low market capitalization that are risky, but have the potential for high reward. At first, these stocks…
Markets could ‘look past’ a temporary US lockdown: Analyst
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Andrew Harmstone from Morgan Stanley Investment Management believes a credible coronavirus policy from the Biden team will be able to mitigate any downside from a potential temporary lockdown to stem the pandemic. 00:40 Mon, Nov 9 20203:03 AM EST
Galaxy Digital’s Michael Novogratz on bitcoin ETFs: An amazing product for consumers & institutions
Galaxy Digital CEO Michael Novogratz joins ‘Squawk Box’ to discuss the SEC’s approval of spot bitcoin ETFs, how his bitcoin ETF with Invesco will differ from other ETF offerings, what it means for Wall Street investors, the impact on crypto at large, the 2024 election, and more.
Options traders placing bullish bets on Micron ahead of quarterly results
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Mike Khouw, Optimize Advisors president, joins CNBC’s Melissa Lee and the Options Action traders to talk Micron. 01:05 Tue, Sep 26 20236:28 PM EDT
Oppenheimer’s Colin Rusch on Wolfspeed shares: There’s substantial upside to earnings growth
Colin Rusch, Oppenheimer, joins ‘Closing Bell’ to discuss Wolfspeed shares turning positive on the year.
